

KARIM, L., MCINTOSH, T., JEBARA, T., PFLEGER, D., OSPREY, A. and CUNNINGHAM, S. [2024]. Investigating practice integration of independent prescribing by community pharmacists using normalization process theory: a cross-sectional survey. *International journal of clinical pharmacy* [online], (accepted). To be made available from: <https://doi.org/10.1007/s11096-024-01733-x>

# Investigating practice integration of independent prescribing by community pharmacists using normalization process theory: a cross-sectional survey.

KARIM, L., MCINTOSH, T., JEBARA, T., PFLEGER, D., OSPREY, A. and CUNNINGHAM, S.

2024

*This is the accepted manuscript version of the above article. The version of record will eventually be published open access and made available from: <https://doi.org/10.1007/s11096-024-01733-x>*

# **Investigating practice integration of independent prescribing by community pharmacists using Normalization Process Theory: a cross-sectional survey**

**Karim, L<sup>a</sup>, McIntosh T<sup>a</sup>, Jebara T<sup>b</sup>, Pflieger D<sup>c</sup>, Osprey A<sup>d</sup>, Cunningham S<sup>a</sup>**

- a. School of Pharmacy & Life Sciences, Robert Gordon University, Garthdee Road, Aberdeen, AB10 7GJ
- b. Health Services & Population Science Department, Institute of Psychiatry, Psychology & Neuroscience, De Crespigny Park, King's College London, London, SE5 8AF
- c. Pharmacy & Medicines Directorate, Westholme, Woodend Hospital, Queens Road, Aberdeen, AB15 6LS
- d. Community Pharmacy Scotland, 42 Queen Street, Edinburgh, EH2 3NH

## **Corresponding author:**

Professor Scott Cunningham

Professor of Pharmacy Education & Practice, School of Pharmacy & Life Sciences, Robert Gordon University, Garthdee Road, Aberdeen, AB10 7GJ

Email: [s.cunningham@rgu.ac.uk](mailto:s.cunningham@rgu.ac.uk)

**Declarations of interest:** none

## **Authors contributions:**

Karim L: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Roles/Writing - original draft; Writing - review & editing.

McIntosh T: Conceptualization; Formal analysis; Investigation; Methodology; Project administration; Supervision; Validation; Roles/Writing - original draft; Writing - review & editing.

Jebara T: Data curation; Formal analysis; Investigation; Methodology; Validation; Roles/Writing - original draft; Writing - review & editing.

Pflieger D: Conceptualization; Funding acquisition; Resources; Supervision; Roles/Writing - original draft; Writing - review & editing.

Osprey A: Conceptualization; Resources; Software; Supervision; Visualization; Roles/Writing - original draft; Writing - review & editing.

Cunningham S: Conceptualization; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Supervision; Validation; Roles/Writing - original draft; Writing - review & editing.

## 1 **Abstract**

### 2 **Investigating practice integration of independent prescribing by** 3 **community pharmacists using Normalization Process Theory: a cross-** 4 **sectional survey**

#### 5 Background

6 Independent prescribing (IP) has not been extensively investigated in  
7 community pharmacy (CP). Normalization Process Theory (NPT) constructs help  
8 explain how interventions are integrated into practice and include: 'coherence'  
9 (understanding), 'cognitive participation' (what promotes engagement),  
10 'collective action' (integration with existing systems), 'reflexive monitoring'  
11 (evaluation).

#### 12 Aim

13 To use NPT to investigate the integration of pharmacist IP in CP.

#### 14 Method

15 NHS Scotland Pharmacy First Plus (PFP) is a community pharmacy IP service.  
16 Questionnaire items were developed using the NPT derived Normalisation  
17 Measure Development (NoMAD) tool for an online survey of all PFP IP  
18 pharmacists. Demographic data were analysed descriptively and scale scores  
19 (calculated from item scores for the 4 NPT constructs) were used for inferential  
20 analysis.

#### 21 Results

22 There was a 73% (88/120) response rate. Greater than 90% 'strongly agreed' /  
23 'agreed' to NoMAD items relating to most NPT constructs. However, responses to  
24 'collective action' items were diverse with more participants answering 'neither  
25 agree nor disagree' or 'disagree'. A statistically significant difference in NPT  
26 construct scale scores with significant p-values (ranging from  $p < 0.001$  to  
27  $p = 0.033$ ) was shown on all the NPT constructs for the variable 'On average, how  
28 often do you consult with patients under the PFP service?'.  
29

#### 29 Conclusion

30 This theory-based work offers perspectives on IP integration within CP. Despite  
31 its geographic focus this work offers insights relevant to wider contexts on IP  
32 integration. It shows 'collective action' focused 'organisation' and 'group process'  
33 challenges with a need for further work on staff training, resource availability  
34 and utilisation, working relationships, communication and management.

35

36 Keywords: pharmaceutical services, community pharmacy services, non-medical  
37 prescribing, implementation science, systems theory

38

### 39 Impact Statements

- 40 • Independent prescribing (IP) by pharmacists exists in several countries  
41 and can impact positively patient services but its integration into  
42 community pharmacy (CP) has not been extensively investigated
- 43 • The use of theory positively impacts the quality and relevance of  
44 pharmacy-based research and so this study uses the Normalization  
45 Process Theory (NPT)
- 46 • There is positivity to integration of IP in CP but a need for further  
47 consideration of aspects of the NPT 'collective action' construct ie. how IP  
48 integrates with existing systems and practices
- 49 • Further work in this context is required on staff training, resource  
50 availability and utilisation, working relationships, communication and  
51 management.

52

53

## 54 **Introduction**

55 Practice dimensions for health professionals are shifting with the integration of  
56 prescribing by non-medical health professionals. This includes pharmacists in the  
57 United Kingdom (UK), United States of America (USA), Canada and New Zealand  
58 [1,2,3,4]. Non-medical prescribing (NMP) has stated aims of improving patient  
59 care, patient safety and access to medicines and enhancing the utility of the  
60 skillset of health professionals [5,6,7].

61 Models of NMP practice are developing at differing rates and in differing ways  
62 around the world [8,9]. The model that allows greatest flexibility for advancing  
63 patient care and professional practice is the independent prescribing (IP) model.  
64 In the UK, in 2006, regulations came into effect to allow pharmacists to  
65 prescribe independently [10] following successful completion of a certified  
66 training course [11]. In the USA, prescriptive authority using an IP 'standard of  
67 care' model has been implemented in a small number of states and is similar to  
68 the UK model of IP [2,12]. In Canada, pharmacists have had IP rights for over  
69 10 years [13] and the advantages of this model have been highlighted [14]. In  
70 New Zealand, it has been noted that there is variation in terms of regulation,  
71 educational programmes and prescribing competencies used by the different  
72 prescribing health professionals. The IP model is not yet available for  
73 pharmacists [15].

74 There is evidence relating to perceptions, views and attitudes towards IP in  
75 community pharmacy (CP) from Canada and the UK. This shows general  
76 enthusiasm and positivity, tempered with caution and forbearance [16,17,18,19]  
77 which can affect the integration of pharmacist prescribing into practice [20].

78 There is evidence that a range of factors at individual, organisational, regulatory  
79 and policy making levels influence the implementation of pharmacist IP in CP  
80 [18,21]. In wider contexts, barriers to implementation of IPs have been  
81 summarised in a systematic review and are noted to exist at the 'preparation',  
82 'training', 'transition' and 'sustainment' stages of implementation [22].

83 Given these challenges changing legislation and professional guidance is not  
84 sufficient to embed new practices [20]. Makowsky and colleagues used the  
85 'Diffusion of Innovations' model in healthcare and showed a breadth of system-  
86 related factors influencing pharmacists taking on prescribing roles [23]. There is  
87 a need to extend the use of theory-based whole systems approaches to research

88 in this area [24]. Robust research of CP services can be guided by theory-based  
89 implementation science approaches [25,26].

90 One such approach is the Normalization Process Theory (NPT) [27] which has  
91 four components (Figure 1): 'coherence' (meaningful qualities and  
92 understanding of benefits and possibilities of an intervention), 'cognitive  
93 participation' (what promotes enrolment in and engagement with an  
94 intervention), 'collective action' (how an intervention integrates with existing  
95 systems and practices), 'reflexive monitoring' (how integration of an intervention  
96 is evaluated and assessed). NPT is therefore designed to help explain how  
97 interventions are integrated (i.e. normalised) into practice and how the  
98 interventions work from early to later stages when embedded [28]. NPT was  
99 considered appropriate to use for this planned research in view of the need not  
100 simply to describe but consider relationships between factors influencing the  
101 implementation process at both individual practitioner and organisational levels  
102 and its use in this context has been advocated by other researchers [9].

103 [Insert Figure 1]

104 In the UK, in November 2020, National Health Service (NHS) Scotland launched  
105 NHS Pharmacy First Plus (PFP) with the aim of supporting patients to access  
106 advice and treatment for common clinical conditions from pharmacist IPs in CP  
107 (within their competence and professional indemnity arrangements) rather than  
108 being referred to other healthcare professionals in other settings [29,30]. There  
109 are no published research findings around this newly implemented initiative and  
110 this gap in evidence provides the rationale for this study.

### 111 **Aim**

112 The aim of this work was to use NPT to investigate the integration of pharmacist  
113 IP in CP in the context of NHS Pharmacy First Plus.

### 114 **Ethics approval**

115 Ethical approval (S307) was granted by Robert Gordon University, School of  
116 Pharmacy and Life Sciences on 2nd February 2022. The study was confirmed as  
117 exempt from full NHS ethical review by West of Scotland Research Ethics  
118 Service.

119

## 120 **Method**

### 121 **Study design and Setting**

122 This cross-sectional online survey was carried out in CPs in Scotland in each of  
123 the 14 geographic Health Boards.

### 124 **Sample and sample size**

125 At the time of the study (April to June 2022) a total of 120 CPs offering PFP were  
126 identified via NHS Board CP leads. All of these were invited to participate in the  
127 study with a request for an IP qualified pharmacist in each CP to complete the  
128 questionnaire. Given this the estimated population sample was 120 IP qualified  
129 pharmacists and using an online survey sample size calculator with: 95%  
130 confidence Level, 120 population and 6% margin of error the ideal sample size is  
131 83 [<https://www.qualtrics.com/blog/calculating-sample-size/>].

### 132 **Development of data collection tools**

133 Demographic information on participants (Table 1) was collected. The  
134 Normalization Measure Development (NoMAD) items were used to develop the  
135 questionnaire for this study. NoMAD is a customisable tool based on NPT that is  
136 designed to capture aspects of intervention implementation into practices [31].  
137 The items included (Table 2 and 3): general questions related to perceptions of  
138 'familiarity' and 'normality of the PFP service and items for each of the NPT  
139 constructs: coherence, cognitive participation, collective action and reflexive  
140 monitoring. Five-point semantic differential ('not at all' to 'completely') and  
141 Likert scales ('strongly agree' to 'strongly disagree') were used. A section for  
142 open comments was provided at the end of the questionnaire.

143 Face and content validity was tested using a sample of key IP and CP  
144 stakeholders in each Health Board across Scotland. Additionally, 'Think Aloud'  
145 testing [32] was carried out with three pharmacists with experience of pharmacy  
146 practice, education and academic research. This involved separate one-to-one  
147 online meetings with the lead researcher (LK). All aspects of data collection  
148 documentation were included i.e. the email invitation, instructions and  
149 questionnaire items. Each aspect was systematically considered, and the  
150 pharmacists were encouraged to verbalise their thoughts and understanding of  
151 each aspect and to enable the lead researcher to explore any areas of ambiguity  
152 and lack of clarity. Finally, the online questionnaire was piloted with five IPs who  
153 met the inclusion criteria to test the integrity and useability of the online

154 systems. Pilot data were included in the final data set since no changes were  
155 made.

## 156 **Data collection**

157 The questionnaire was hosted on the JISC Online Surveys  
158 ([www.onlinesurveys.ac.uk](http://www.onlinesurveys.ac.uk)). In April 2022 a link to the online questionnaire was  
159 sent via email by contacts at each regional Scottish Health Board to all  
160 community pharmacies across Scotland who offer PFP. Three reminder emails  
161 were sent at 2 weekly intervals and the survey was closed at the start of June  
162 2022. A participant information sheet was provided and consent to participate  
163 was assumed through completion and submission of the questionnaire.

## 164 **Analysis**

165 Data were exported to the IBM SPSS Statistics (SPSS Inc., Cary, NC version  
166 21.0). Analysis was guided by the research aim and included descriptive and  
167 inferential statistics including Cronbach's alpha scale item internal consistency  
168 testing (describing, with alpha values between 0 to 1, the extent to which the  
169 NPT construct scale score items are related to each other and so the construct,  
170 higher alpha values show higher internal consistency) and significance testing of  
171 scale scores with relevant nominal data using the Kruskal-Wallis test (considered  
172 statistically significant at a p-value of less than 0.05). The NoMAD related items  
173 were scored and analysed using the methods outlined by the original authors  
174 [31] with Likert scale items scored 5 for 'strongly agree' to 1 for 'strongly  
175 disagree'. Open comments were analysed using framework analysis to identify  
176 key themes [33] and are presented in 'Supplementary Materials'.

177

178



179 **Results**

180 **Demographic data**

181 The response rate was 88 of the 120 (73%) pharmacists who at the time of the  
182 study were providing PFP. Table 1 shows that the majority of respondents were  
183 female (63%, 55/88), under 40 years old (51%, 45/88), had worked in CP for  
184 more than 15 years (56%, 49/88) and had been qualified as an IP for less than  
185 5 years (59%, 52/88).

186

187 [INSERT Table 1]

188

189 Responses were received from pharmacists working in all the Health Board areas  
190 of Scotland where PFP was being provided. There was a greater number of  
191 responses (60%, 53/88) from the larger Health Board areas of Greater Glasgow  
192 and Clyde (population served 1.15 million), NHS Lothian (population served 0.8  
193 million), NHS Grampian (population served 0.6 million) and NHS Tayside  
194 (population served 0.4 million). There was also strong representation from  
195 Health Boards with more rurality including NHS Highland, NHS Grampian, and  
196 NHS Tayside (38%, 33/88).

197

198 **NHS Pharmacy First Plus: activity and staffing levels**

199

200 Table 1 shows that seventy-six percent (67/88) of respondents indicated that on  
201 average they consulted with patients under PFP service six or more times a  
202 week. The majority (66%, 58/88) indicated they had 4 or more staff working  
203 alongside them in their pharmacy when offering PFP. Figure 2 provides data on  
204 respondents' reports of the characteristics of staff working alongside them on an  
205 average day when they were offering PFP. The majority (58%, 41/71) indicated  
206 that they provided the service while working as the only pharmacist in the CP.  
207 Sixty percent (44/73) had 1 or more accuracy checking technicians, 64%  
208 (42/66) one or more pharmacy technicians, 75% (60/80) had 2 or more  
209 dispensing assistants. Thirty-one percent (19/62) of respondents had a  
210 Foundation Training Year (formerly pre-registration) pharmacist.

211

212 [INSERT Figure 2]

213

214

## 215 **NoMAD (NPT) Questionnaire item responses**

216

217 The NoMAD questionnaire items include 'General Assessment' questions that  
218 provide an indication of familiarity and how normal the respondent feels a  
219 service is in their working practice. Table 2 indicates that respondents were  
220 generally positive about 'familiarity' and 'normality' with medians of 3.5 (Inter-  
221 quartile range (IQR) 3 to 5) and 4 (IQR 3 to 5) respectively.

222

223 [INSERT Table 2]

224 Table 3 provides data on the responses to each of the items devised to relate to  
225 the PFP service in line with the NPT constructs of 'coherence', 'cognitive  
226 participation', 'collective actions' and 'reflexive monitoring'. Generally, there  
227 were high levels of agreement with more than 90% of the respondents 'strongly  
228 agreeing' or 'agreeing' to all items relating to 'coherence' and most relating to  
229 'cognitive participation'. One outlier was the item 'There are key people in my  
230 organisation who drive PFP forward' with only 53% (47/88) in agreement.  
231 Similarly, with 'reflexive monitoring' most items had greater than 90% in  
232 agreement with slightly fewer at 87% (77/88) in agreement with the item 'I  
233 have received feedback about the benefits of PFP from my patients'.

234 Responses to the items within the 'collective action' construct were more diverse  
235 with a greater proportion of respondents answering 'neither agree nor disagree'  
236 or disagreeing.

237 [INSERT Table 3]

238 An analysis of open comments provided by respondents indicates respondents'  
239 willingness to adopt and integrate this new service into their already substantial  
240 workloads, and the urgent need to improve communication with GP practices  
241 including access to patient notes to facilitate this. Respondents expressed a  
242 need for additional training and staff resource with many working in a very  
243 demanding role as the sole pharmacist while providing the PFP service. A full  
244 analysis of comments with respondent quotations is provided in 'Supplementary  
245 Materials' provided alongside this article.

246

247

248

249

## 250 **Construct scale scores**

251

252 As outlined above scale scores for each of the four NPT constructs were  
253 calculated through summation of item scores from within each construct for each  
254 respondent. Prior to this the items were tested for internal consistency (i.e. how  
255 well they related to each other) using Cronbach's alpha. Cronbach's alpha ( $\alpha$ )  
256 for each of the four NPT construct groupings showed: 'Coherence' consisted of  
257 four items and  $\alpha = 0.737$ ; 'cognitive participation' had four items and  $\alpha =$   
258  $0.669$ ; 'collective action' comprised eight items and  $\alpha = 0.68$ ; and 'reflexive  
259 monitoring' contained five items and  $\alpha = 0.827$ . The normalisation scale overall  
260 (comprising items across all four constructs), was highly reliable (21 items,  $\alpha =$   
261  $0.852$ ).

262

263 The scale scores for each respondent and construct were used to calculate  
264 range, midpoint and median responses (Table 3) and for further analysis. The  
265 generally positive nature of responses as outlined above is shown through  
266 consideration of the median scores and scale midpoint. The higher the median  
267 above the midpoint the more positive the responses to those items within the  
268 scale. The medians for 'coherence' and 'reflexive monitoring' were 7 and 8 points  
269 above the midpoint respectively. Those for 'cognitive participation' and collective  
270 action were 6 points above the midpoint. The greater diversity of responses to  
271 'collective action' is shown by the larger inter quartile range (IQR) value of 7  
272 compared to the IQR value for other constructs.

273

## 274 **Inferential Statistics**

275

276

277 Statistical testing showed no significant relationships between demographic  
278 characteristics (Table 1) and NoMAD NPT construct scale scores.

279 It was hypothesised that the participants professional experience and frequency  
280 of PFP consultation may have affected the responses to questionnaire items and  
281 so the NPT construct scale scores. The Kruskal-Wallis test was used to test for  
282 differences between NPT construct scale scores by calculating the 'mean rank'  
283 for each category within the professional experience and frequency of  
284 consultation variables (Table 4).

285

286 [INSERT Table 4.]

287

288 'Mean rank' values are similar across the variable categories and there were no  
289 statistically significant relationships between 'How long qualified as pharmacist  
290 independent prescriber' and 'How many years working in community pharmacy?'  
291 (Table 4).

292 The Kruskal-Wallis test revealed that there was a statistically significant  
293 relationship between frequency of PFP consultation activity and scale scores for  
294 all of the NPT constructs: 'coherence' (KW H 7.652,  $p=0.022$ ), 'cognitive  
295 participation' KW H 11.790,  $p=0.033$ , 'collective action' (KW H 7.588,  $p=0.023$   
296 and 'reflexive monitoring' (KW H 20.484,  $p=0.001$ ).

297 Higher 'mean rank' values for the category 'More than 10 times per week' for  
298 variable 'On average, how often do you consult with patients under the  
299 Pharmacy First Plus service?' indicates that those participants that undertook  
300 more PFP activity were more likely to agree to the items and so have positive  
301 views in relation to the NPT construct.

302

## 303 **Discussion**

### 304 Key findings

305 Respondents were generally positive about the service with high levels of  
306 agreement with all the items relating to the NPT constructs of 'coherence',  
307 'cognitive participation' and 'reflexive monitoring'. Responses to 'collective  
308 action' were more diverse with a greater proportion of respondents answering  
309 'neither agree nor disagree' or disagreeing. A statistically significant difference in  
310 NPT construct scale scores with significant p-values (ranging from  $p<0.001$  to  
311  $p=0.033$ ) was shown on all the NPT constructs for the variable 'On average, how  
312 often do you consult with patients under the PFP service?' with higher 'mean  
313 rank' values for 'More than 10 times per week'.

### 314 Strengths and limitations

315 The survey was sent to all community pharmacies in Scotland that at the time  
316 offered PFP with an excellent response from rural Health Boards where PFP has  
317 an important role in improving access to healthcare [34]. The overall response  
318 rate resulted in a sample size that meets the 95% Confidence level. A robust  
319 development process was undertaken using the previously validated NPT derived  
320 NoMAD tool and items were scored and analysed with reference to the methods

321 outlined by the original authors [31, 35]. The Cronbach's alpha calculated for the  
322 items included in each of the four NPT construct groupings showed high internal  
323 consistency.

324 Limitations include a proportionate excess from some NHS Board areas but in  
325 view of the response rate overall it was felt that it would not have been useful to  
326 follow up the non-responders. Notwithstanding that the sample size of 83 was  
327 achieved, the small available sample size means that statistical analysis may be  
328 under-powered and this may have led to no statistical difference findings.

#### 329 Interpretation

330 In relation to shared understanding of IP service provision in CP and so the NPT  
331 construct 'coherence' (Figure 1), respondents indicated high levels of familiarity  
332 with the PFP service. The clear policy for and structure of contracted CP  
333 pharmacist prescribing services in Scotland may be facilitating this [29].  
334 Makowsky and colleagues have highlighted this 'innovation system fit' facet as a  
335 significant factor in pharmacists adopting prescribing practices [23]. This work  
336 did not focus on service users' understanding of community pharmacist  
337 prescribing services but it has been shown there is a need to raise service users'  
338 awareness of such services [36].

339 Regarding the 'cognitive participation' construct (Figure 1), the majority of  
340 respondents had been qualified for IP for less than 5 years. Faruquee and  
341 Guirguis concluded in their scoping review that increased risk and liability are  
342 demotivators for taking on a prescribing role and so activity is often higher in  
343 those with more experience and advanced qualifications [16]. The relatively  
344 recently-qualified participants in this study expressed willingness to engage with  
345 IP in the context of PFP, and these participants' self-reported levels of  
346 prescribing shows that a possible lack of experience and advanced qualifications  
347 does not seem to have negative influence on IP integration.

348 Of relevance to the 'collective action' construct (Figure 1) and specifically  
349 'organizing structures', Edward and colleagues have synthesised the literature on  
350 barriers and facilitators to implementation of NMP in primary care in the UK [22]  
351 and identified the importance of organisational support for early adopters of  
352 prescribing practice. The findings from our work indicate potential organisational  
353 support barriers including a need for further consideration of: managerial /  
354 leadership support, challenges around interprofessional working, and  
355 communication including the availability and use of information communication

356 technology (ICT) systems. The need for improvement in ICT in this context has  
357 recently been highlighted by others [37] along with the need for ICT evaluation  
358 frameworks [38]. ICT is also central to the 'reflexive monitoring' construct to  
359 allow the collation and analysis of prescribing data for audit and feedback  
360 purposes and so quality improvement of patient services.

361 The greater diversity of responses within the 'group processes and norms' aspect  
362 of 'collective action' (Figure 1) indicates that there is a need for even greater  
363 clarity of team members roles, consideration of availability of training and  
364 funding for more staff resource and processes for working and communicating  
365 within teams. The influence of such factors on implementation of pharmacist  
366 prescribing has been shown by others in the primary care context [18,21,39].

367 This work was UK focused where there is a coherent NMP legislative and  
368 regulatory frameworks across the devolved nations, but implementation of IP is  
369 progressing at different rates and in different ways [29,40]. This situation is  
370 reflected in the implementation of the models of IP for pharmacists in other  
371 countries including USA, Canada and New Zealand as outlined above [12,13,15].  
372 Despite this, in an umbrella review [9] and other work [41,42] have highlighted  
373 commonality internationally with respect to models and definitions, legal  
374 frameworks, outcomes and benefits, stakeholder satisfaction and barriers and  
375 facilitators to implementation. It is likely, therefore, that the results of this work  
376 will be applicable internationally.

#### 377 Further work

378 Further research could focus on defining the concepts and contexts relating to  
379 operationalisation of PFP and particularly the 'collective action' facets of the NPT.  
380 This in turn would help to ensure standardisation in relation to further evaluative  
381 studies on integration issues. Specific interventions could then be developed with  
382 cognisance of the Medical Research Council guidance on developing and  
383 evaluating complex interventions [43].

#### 384 **Conclusion**

385 This theory-based work offers a robust and unique perspective on IP integration  
386 within CP. The generally positive findings highlight challenges within the  
387 'collective action' construct and a need to focus on training, staff resource,  
388 working relationships, communication and management. Despite the focus of

389 this work it is likely that these factors are applicable to other jurisdictions and  
390 contexts.

391

392 **Declarations of:**

393 Conflicts of interest: None

394 Funding: This work has been funded by the Scottish Government through a  
395 Scottish Pharmacist Clinical Academic Fellowship for Laura Karim.

396 Acknowledgements: Ashlaich Lockhead for administrative support and Hannah  
397 Upsher-Stuart for proof reading and checking of the manuscript prior to  
398 submission.

399

400 **Supplementary Materials:**

401 S1. Content analysis of open comments

402 S2. Validation of NoMAD derived questionnaire items

403

404

405

406

407

408 **References**

- 409 1 . Graham-Clarke E, Rushton A, Noblet T et al. Non-medical prescribing in the  
410 United Kingdom National Health Service: A systematic policy review. PLoS One.  
411 2019, 14:e0214630. <https://doi.org/10.1371/journal.pone.0214630>
- 412 2. Sachdev G, Kliethermes MA, Vernon V, et al. Current status of prescriptive  
413 authority by pharmacists in the United States. JACPP. 2020, 3(4):807-817.  
414 <https://doi.org/10.1002/jac5.1245>.
- 415 3. Scope of practice: What pharmacists can do across Canada. Canadian  
416 Pharmacists Association. Available at  
417 <https://www.pharmacists.ca/advocacy/scope-of-practice/>. Accessed 06.02.2024.
- 418 4. Raghunandan, R., Marra, C.A., Tordoff, J. et al. Examining non-medical  
419 prescribing trends in New Zealand: 2016–2020. BMC Health Serv Res. 2021, 21,  
420 418. <https://doi.org/10.1186/s12913-021-06435-y>.
- 421 5. UK Department of Health, 2006. Improving patients’ access to medicines: A  
422 guide to implementing nurse and pharmacist independent prescribing within the  
423 NHS in England. [Online]. London: UK Department of Health.  
424 [http://webarchive.nationalarchives.gov.uk/+www.dh.gov.uk/en/Publicationsand](http://webarchive.nationalarchives.gov.uk/+www.dh.gov.uk/en/PublicationsandStatistics/Publications/PublicationsPolicyandGuidance/DH_4133743)  
425 [Statistics/Publications/PublicationsPolicyandGuidance/DH\\_4133743](http://webarchive.nationalarchives.gov.uk/+www.dh.gov.uk/en/PublicationsandStatistics/Publications/PublicationsPolicyandGuidance/DH_4133743). Accessed  
426 06.02.24
- 427 6. Weeks G, George J, Maclure K et al. Non-medical prescribing versus medical  
428 prescribing for acute and chronic disease management in primary and secondary  
429 care. Cochrane Database Syst Rev. 2016;11:CD011227.  
430 <https://doi.org/10.1002/14651858.CD011227.pub2>
- 431 7. Jebara T, Cunningham S, MacLure K et al. Stakeholders' views and  
432 experiences of pharmacist prescribing: a systematic review. Br J Clin Pharmacol.  
433 2018, 84:1883-1905. <https://doi.org/10.1111/bcp.13624>
- 434 8. Cope CP, Abuzour AS, Tully MP. Nonmedical prescribing: where are we now?  
435 Ther Adv Drug Saf. 2016;7:165-72. DOI: 10.1111/bcp.13624.
- 436 9. Stewart D, Jebara T, Cunningham S et al. Future perspectives on nonmedical  
437 prescribing. Ther Adv Drug Saf. 2017, 8:183–197.  
438 <https://doi.org/10.1177/204209861769>
- 439 10. The National Health Service (Miscellaneous Amendments Relating to  
440 Independent Prescribing) Regulations 2006, Stat. 913. Available from  
441 <https://www.legislation.gov.uk/uksi/2006/913/made>. Accessed 06.02.2024.
- 442 11. Royal Pharmaceutical Society of Great Britain, 2022. Pharmacist  
443 Independent Prescribers [Online]. London: Royal Pharmaceutical Society.  
444 Available from [https://www.rpharms.com/recognition/all-our-campaigns/policy-](https://www.rpharms.com/recognition/all-our-campaigns/policy-a-z/pharmacist-independent-prescribers)  
445 [a-z/pharmacist-independent-prescribers](https://www.rpharms.com/recognition/all-our-campaigns/policy-a-z/pharmacist-independent-prescribers). Accessed 06.02.2024.
- 446 12. Alex J. Adams, Krystalyn K. Weaver, Jennifer Athay Adams, Revisiting the  
447 continuum of pharmacist prescriptive authority. JAPhA. 2023, 63(5):1508-1514.  
448 <https://doi.org/10.1016/j.japh.2023.06.025>
- 449 13. Law MR, Ma T, Fisher J, et al. Independent pharmacist prescribing in Canada.  
450 Can Pharm J (Ott). 2012, 145(1):17-23.e1. [https://doi.org/10.3821/1913-701X-](https://doi.org/10.3821/1913-701X-145.1.17)  
451 [145.1.17](https://doi.org/10.3821/1913-701X-145.1.17)



- 452 14. Tsuyuki RT, Watson KE. Why pharmacist prescribing needs to be  
453 independent. *Can Pharm J (Ott)*. 2020, 153(2):67-69.  
454 <https://doi.org/10.1177/1715163520904366>
- 455 15. Raghunandan R, Tordoff J, Smith A. Non-medical prescribing in New  
456 Zealand: an overview of prescribing rights, service delivery models and training.  
457 *Ther Adv Drug Saf*. 2017, 8(11):349-360.  
458 <https://doi.org/10.1177/2042098617723312>
- 459 16. Faruquee CF & Guirguis LM,. A scoping review of research on the prescribing  
460 practice of Canadian pharmacists. *Can Pharm J*. 2015, 148:325-348.  
461 <https://doi.org/10.1177/17151635156083>
- 462 17. Lewis J, Barry AR, Bellefeuille K, et al. Perceptions of Independent  
463 Pharmacist Prescribing among Health Authority- and Community-Based  
464 Pharmacists in Northern British Columbia. *Pharmacy (Basel)*. 2021, 9:92.  
465 <https://doi.org/10.3390/pharmacy9020092>
- 466 18. Feehan M, Durante R, Ruble J, et al. Qualitative interviews regarding  
467 pharmacist prescribing in the community setting. *Am J Health Syst Pharm*. 2016,  
468 73:1456-1461. <https://doi.org/10.2146/ajhp150691>
- 469 19. George J, Pflieger D, McCaig D, et al. Independent prescribing by  
470 pharmacists: a study of the awareness, views and attitudes of Scottish  
471 community pharmacists. *Pharm World Sci*. 2006, 28:45-53. DOI:  
472 10.1007/s11096-006-9018-6.
- 473 20. Adams, A. Pharmacist scope of practice expansion: The virtue of  
474 forbearance. *JACCP*. 2021, 4(9):1067-1069. <https://doi.org/10.1002/jac5.1465>
- 475 21. Isenor JE, Minard LV, Stewart SA et al. Identification of the relationship  
476 between barriers and facilitators of pharmacist prescribing and self-reported  
477 prescribing activity using the theoretical domains framework. *Res Social Adm  
478 Pharm*. 2018, 14:784-791. <https://doi.org/10.1016/j.sapharm.2017.10.004>
- 479 22. Edwards J, Coward M, Carey N. Barriers and facilitators to implementation of  
480 non-medical independent prescribing in primary care in the UK: a qualitative  
481 systematic review. *BMJ Open*. 2022, 12:e052227. doi: 10.1136/bmjopen-2021-  
482 052227. <http://dx.doi.org/10.1136/bmjopen-2021-052227>
- 483 23. Makowsky, M.J., Guirguis, L.M., Hughes, C.A. et al. Factors influencing  
484 pharmacists' adoption of prescribing: qualitative application of the diffusion of  
485 innovations theory. *Implementation Sci*. 2013, 8:109.  
486 <https://doi.org/10.1186/1748-5908-8-109>.
- 487 24. Stewart D & Klein S. The use of theory in research. *Int J Clin Pharm*. 2016,  
488 38:615-619. <https://doi.org/10.1007/s11096-015-0216-y>
- 489 25. Shoemaker SJ, Curran GM, Swan H, et al. Application of the Consolidated  
490 Framework for Implementation Research to community pharmacy: A framework  
491 for implementation research on pharmacy services. *Res Social Adm Pharm*.  
492 2017, 13:905-913. <https://doi.org/10.1016/j.sapharm.2017.06.001>
- 493 26. Nilsen, P. Making sense of implementation theories, models and frameworks.  
494 *Implementation Sci*. 2015, 10:53. <https://doi.org/10.1186/s13012-015-0242-0>.

- 495 27. Murray E, Treweek S, Pope C, et al. Normalisation process theory: a  
496 framework for developing, evaluating and implementing complex interventions.  
497 BMC Med. 2010, 8:63. <https://doi.org/10.1186/1741-7015-8-63>
- 498 28. May CR, Mair F, Finch T et al. Development of a theory of implementation  
499 and integration: Normalization Process Theory. Implement Sci. 2009, 4:29.  
500 <https://doi.org/10.1186/1748-5908-4-29>.
- 501 29. Pharmacy and Medicine Division. PCA(P) (2020) 16, Community pharmacy –  
502 national career pathway and introduction of a common clinical conditions  
503 independent prescribing service (NHS Pharmacy First Plus). Edinburgh: Scottish  
504 Government; 2020. Available from  
505 [https://www.sehd.scot.nhs.uk/pca/PCA2020\(P\)16.pdf](https://www.sehd.scot.nhs.uk/pca/PCA2020(P)16.pdf). Accessed 06.02.2024.
- 506 30. NHS Inform. NHS Pharmacy First Scotland. Available from  
507 [https://www.nhsinform.scot/care-support-and-rights/nhs-](https://www.nhsinform.scot/care-support-and-rights/nhs-services/pharmacy/nhs-pharmacy-first-scotland)  
508 [services/pharmacy/nhs-pharmacy-first-scotland](https://www.nhsinform.scot/care-support-and-rights/nhs-services/pharmacy/nhs-pharmacy-first-scotland). Accessed 06.02.2024.
- 509 31. Finch TL, Girling M, May CR et al. Improving the normalization of complex  
510 interventions: part 2 - validation of the NoMAD instrument for assessing  
511 implementation work based on normalization process theory (NPT). BMC Med  
512 Res Methodol. 2018, 18:135. <https://doi.org/10.1186/s12874-018-0591-x>
- 513 32. Eccles D & Arsal G. The think aloud method: what is it and how do I use it?  
514 Qualitative Research in Sport, Exercise and Health [Online]. London: 2017;514-  
515 531. <https://doi.org/10.1080/2159676x.2017.1331501>
- 516 33. Srivastava A & Thomson S. Framework Analysis: A Qualitative Methodology  
517 for Applied Policy Research. J Admin Gov. 2008, 4:72-79.
- 518 34. Scottish Government Spatial Data.gov.scot. Urban Rural Classification -  
519 Scotland. Available from [https://www.data.gov.uk/dataset/f00387c5-7858-4d75-](https://www.data.gov.uk/dataset/f00387c5-7858-4d75-977b-bfdb35300e7f/urban-rural-classification-scotland)  
520 [977b-bfdb35300e7f/urban-rural-classification-scotland](https://www.data.gov.uk/dataset/f00387c5-7858-4d75-977b-bfdb35300e7f/urban-rural-classification-scotland). Accessed 06.02.2024.
- 521 35. Huddleston L, Turner J, Eborall H et al. Application of normalisation process  
522 theory in understanding implementation processes in primary care settings in  
523 the UK: a systematic review. BMC Fam Pract. 2020, 21:52.  
524 <https://doi.org/10.1186/s12875-020-01107-y>
- 525 36. Famiyeh IM, MacKeigan L, Thompson A, et al. Exploring pharmacy service  
526 users' support for and willingness to use community pharmacist prescribing  
527 services. Res Social Adm Pharm. 2019, 15:575-583.  
528 <https://doi.org/10.1016/j.sapharm.2018.07.016>
- 529 37. Ogundipe A, Sim TF, Emmerton L. The case to improve technologies for  
530 pharmacists' prescribing. IJPP. 2023, 31(1):113-115,  
531 <https://doi.org/10.1093/ijpp/riac075>.
- 532 38. Ogundipe A, Sim TF, Emmerton L. Health information communication  
533 technology evaluation frameworks for pharmacist prescribing: A systematic  
534 scoping review. Res Social Adm Pharm. 2023, 19(2):218-234,  
535 <https://doi.org/10.1016/j.sapharm.2022.09.010>.
- 536 39. Buist, E., McLelland, R., Rushworth, G.F. et al. An evaluation of mental health  
537 clinical pharmacist independent prescribers within general practice in remote and

- 538 rural Scotland. *Int J Clin Pharm.* 2019, 41:1138–1142.  
539 <https://doi.org/10.1007/s11096-019-00897-1>
- 540 40. NHS Wales Shared Services Partnership. Pharmacy Independent Prescribing  
541 Service: Common Ailments and Contraception. Service Specification for a  
542 National Directed Service. Available from:  
543 [https://nwssp.nhs.wales/ourservices/primary-care-services/primary-care-](https://nwssp.nhs.wales/ourservices/primary-care-services/primary-care-services-documents/ccps-documents/pharmacy-ip-services/pips-common-ailments-and-contraception-service-specification/)  
544 [services-documents/ccps-documents/pharmacy-ip-services/pips-common-](https://nwssp.nhs.wales/ourservices/primary-care-services/primary-care-services-documents/ccps-documents/pharmacy-ip-services/pips-common-ailments-and-contraception-service-specification/)  
545 [ailments-and-contraception-service-specification/](https://nwssp.nhs.wales/ourservices/primary-care-services/primary-care-services-documents/ccps-documents/pharmacy-ip-services/pips-common-ailments-and-contraception-service-specification/). Accessed 06.02.2024.
- 546 41. Stewart, D., Pallivalapila, A., Thomas, B. et al. A theoretically informed,  
547 mixed-methods study of pharmacists' aspirations and readiness to implement  
548 pharmacist prescribing. *Int J Clin Pharm.* 2021, 43:1638–1650.  
549 <https://doi.org/10.1007/s11096-021-01296-1>
- 550 42. Diab, M.I., Ibrahim, A., Abdallah, O. et al. Perspectives of future pharmacists  
551 on the potential for development and implementation of pharmacist prescribing  
552 in Qatar. *Int J Clin Pharm.* 2020, 42: 110–123. [https://doi.org/10.1007/s11096-](https://doi.org/10.1007/s11096-019-00946-9)  
553 [019-00946-9](https://doi.org/10.1007/s11096-019-00946-9)
- 554 43. Skivington K, Matthews L, Simpson SA, et al. A new framework for  
555 developing and evaluating complex interventions: update of Medical Research  
556 Council guidance. *BMJ.* 2021, 374:n2061. <https://doi.org/10.1136/bmj.n2061>
- 557
- 558

560 **Table 1: Demographic data of questionnaire respondents (N=88)**

Demographic category	Number of respondents (%)
Age <ul style="list-style-type: none"> <li>less than 30 years</li> <li>30-40 years</li> <li>41-50 years</li> <li>51-60 years</li> <li>more than greater than 60 years</li> </ul>	8 (9) 37 (42) 25 (28) 12 (13) 6 (7)
Gender <ul style="list-style-type: none"> <li>Male</li> <li>Female</li> <li>Would rather not say</li> <li>Other</li> </ul>	31 (35) 55 (63) 2 (2) 0
Health Board of main practice setting <ul style="list-style-type: none"> <li>NHS Grampian</li> <li>NHS Greater Glasgow and Clyde</li> <li>NHS Fife</li> <li>NHS Lothian</li> <li>NHS Tayside</li> <li>NHS Highland</li> <li>NHS Lanarkshire</li> <li>NHS Ayrshire and Arran</li> <li>NHS Dumfries and Galloway</li> <li>NHS Borders</li> <li>NHS Forth Valley</li> <li>NHS Western isles</li> <li>NHS Orkney</li> <li>NHS Shetland</li> </ul>	18 (21) 16 (18) 12 (14) 10 (11) 9 (10) 6 (7) 6 (7) 5 (6) 3 (3) 2 (2) 1 (1) 0 0 0
Employment category <ul style="list-style-type: none"> <li>Pharmacy Manager</li> <li>Pharmacist</li> <li>Superintendent Pharmacist</li> <li>Other (including Locum, Pharmacy Owner Contractor, Area Manager, Pharmacy Owner, Area Manager)</li> </ul>	42 (48) 28 (32) 24 (27) 8 (9)
How many staff do you have working alongside you in your pharmacy when offering Pharmacy First Plus? <ul style="list-style-type: none"> <li>3 or fewer staff</li> <li>4-6 staff</li> <li>Over 6 staff</li> </ul>	30 (34) 36 (41) 22 (25)

561

562 **Table 2. General assessment responses for the Normalization MeASURE**  
563 **Development (NoMAD) questionnaire items relating to familiarity and**  
564 **normality (N=88)**

Item	Not at all					Median (IQR)
	1	2	3	4	5	
When you deliver Pharmacy First Plus, how FAMILIAR does it feel to you?	4 (5)	11 (13)	29 (33)	26 (30)	18 (21)	3.5 (3 to 5)
To what extent do you feel Pharmacy First Plus is currently a NORMAL PART of your work?	4 (5)	8 (9)	22 (25)	27 (31)	27 (31)	4 (3 to 5)

565

**Table 3. Response, internal consistency and scale scores data for Normalization MeASURE Development (NoMAD) items (N=88)**

NPT Construct	Statement	Strongly agree	Agree	Neither agree not disagree	Disagree	Strongly disagree
		n (%)	n (%)	n (%)	n (%)	n (%)
COHERENCE	I am aware of how Pharmacy First Plus differs from usual ways of working in community pharmacy	50 (56.8)	35 (39.8)	1 (1.1)	2 (2.3)	0
	Staff in this pharmacy have a shared understanding of the purpose of Pharmacy First Plus	41 (46.6)	39 (44.3)	4 (4.5)	4 (4.5)	0
	I understand how Pharmacy First Plus affects the nature of my own work e.g., my decision-making process/processes to undertake consultations etc.	52 (59.1)	36 (40.9)	0	0	0
	I can see the potential value of Pharmacy First Plus for my role as a pharmacist independent prescriber	70 (79.5)	16 (18.2)	2 (2.3)	0	0
	<i>Internal consistency: Cronbach's alpha 0.737</i> <i>Scale score: Range 4 to 20, Midpoint 12, Median 19 (IQR 17 -20)</i>					
COGNITIVE PARTICIPATION	There are key people in my organisation who drive Pharmacy First Plus forward	35 (39.8)	28 (31.8)	19 (21.6)	3 (3.4)	3 (3.4)
	I believe that participating in Pharmacy First Plus is an integral part of my role	51 (58)	31 (35.2)	3 (3.4)	3 (3.4)	0
	I am open to working in new ways to effectively offer Pharmacy First Plus	61 (69.3)	25 (28.4)	2 (2.3)	0	0
	I intend to actively engage with Pharmacy First Plus when required	63 (71.6)	25 (28.4)	0	0	0
	<i>Internal consistency: Cronbach's alpha 0.669</i> <i>Scale score: Range 4 to 20, Midpoint 12, Median 18 (IQR 16 -20)</i>					
COLLECTIVE ACTION	I can easily integrate Pharmacy First Plus into my current workflow in the pharmacy	18 (20.5)	28 (31.8)	25 (28.4)	14 (15.9)	3 (3.4)
	Pharmacy First Plus disrupts working relationships within the pharmacy*	1 (1.1)	6 (6.8)	14 (15.9)	37 (42)	30 (34.1)
	I have confidence in other pharmacist's ability to offer Pharmacy First Plus	25 (28.4)	29 (33)	26 (29.5)	6 (6.8)	2 (2.3)
	Tasks are assigned to those with skills appropriate to Pharmacy First Plus	33 (37.5)	36 (40.9)	19 (21.6)	0	0
	Sufficient training is provided to staff	17 (19.3)	35 (39.8)	24 (27.3)	12 (13.6)	0
	Trained staff often offer Pharmacy First Plus to eligible patients	20 (22.7)	44 (50)	14 (15.9)	7 (8)	3 (3.4)
	Sufficient staff are available to support me in offering Pharmacy First Plus	15 (17)	31 (35.2)	19 (21.6)	18 (20.5)	5 (5.7)
	Management of the community pharmacy adequately supports Pharmacy First Plus	23 (26.1)	36 (40.9)	19 (21.6)	7 (8)	3 (3.4)
<i>Internal consistency: Cronbach's alpha 0.680</i> <i>Scale score: Range 8 to 40, Midpoint 24, Median 30 (IQR 26-33)</i>						
REFLEXIVE MONITORING	I have received feedback about the benefits of Pharmacy First Plus from my patients	39 (44.3)	38 (43.2)	10 (11.4)	1 (1.1)	0
	The staff within my pharmacy believe that Pharmacy First Plus is beneficial to our patients	45 (51.1)	38 (43.2)	5 (5.7)	0	0
	I value the effects that Pharmacy First Plus has had on my professional development	60 (68.2)	24 (27.3)	4 (4.5)	0	0
	I think feedback about Pharmacy First Plus can be used to improve it in the future	55 (62.5)	32 (36.4)	1 (1.1)	0	0
	I can modify how I deliver Pharmacy First Plus in response to feedback if necessary	50 (56.8)	37 (42)	1 (1.1)	0	0
<i>Internal consistency: Cronbach's alpha 0.827</i> <i>Scale score: Range 5 to 25, Midpoint 15, Median 23 (IQR 20-25)</i>						

\*Item reversed scored

570

571 **Table 4. Statistical relationships between NPT construct scale scores,**  
 572 **participant professional experience and frequency of NHS Pharmacy**  
 573 **First Plus consultation (N=88).**

<b>Participant professional experience and frequency of consultation</b>	<b>n</b>	<b>Coherence</b>	<b>Cognitive Participation</b>	<b>Collective Action</b>	<b>Reflexive Monitoring</b>
		Scale score mean rank* / 'p value'	Scale score mean rank / 'p value'	Scale score mean rank / 'p value'	Scale score mean rank / 'p value'
How long qualified as pharmacist independent prescriber					
• less than 1 year	16	39.5	38.34	40.28	39.88
• 1-5 years	36	47.11	45.1	44.31	49.21
• 6-10 years	18	49.69	50.69	50.67	44.39
• greater than 10 years	18	38.53	42.58	42.47	39.31
		/ p=0.407	/ p=0.533	/ p=0.457	/ p=0.658
How many years working in community pharmacy?					
• less than 1 year	0	0	0	0	0
• 1-2 years	0	0	0	0	0
• 3-5 years	3	45.50	17.33	27.00	36.33
• 6-10 years	20	53.88	48.10	48.88	50.33
• 11-15 years	16	46.19	51.13	46.31	45.63
• greater than 15 years	49	40.06	42.53	43.19	42.26
		/ p=0.209	/ p=0.147	/ p=0.608	/ p=0.529
On average, how often do you consult with patients under the Pharmacy First Plus service?					
• Never	0	0	0	0	0
• Fewer than 5 times per week	21	37.38	34.24	33.05	37.88
• 6-10 times per week	38	40.62	40.57	44.22	35.08
• More than 10 times per week	29	54.74	57.09	53.16	61.64
		/ p=0.022	/ p=0.003	/ p=0.023	/ p<0.001

574 Footnote:\*Kruskal-Wallis used to test for differences between NPT construct scale scores mean ranks (and so  
 575 median values) across 'experience' and 'frequency of consultation' variables.

576


577

578

579

580

581



582

583

584

NB: 'Practice' in the context of this research is 'Pharmacist Independent Prescribing' within community pharmacy

585

586


\*Adapted from May C & Finch T. Implementing, Embedding, and Integrating Practices: An Outline of Normalization Process Theory. Sociology. 2009, 43(3): 535-554.

587

588

**Figure 1 Normalization Process Theory (NPT) – an illustration of the components\***

589



590

591

592

593

**Figure 2. Additional staff working alongside responding independent prescribing pharmacists when providing NHS Pharmacy First Plus (N=88, some missing data)**